The Long Run with Luke Timmerman
Timmerman Report
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Episodes
Mentioned books
Oct 15, 2024 • 1h 4min
Ep166: Chris Garcia on Engineering Protein Drugs for Cancer, Autoimmunity
Chris Garcia, a biochemistry professor at Stanford and biotech entrepreneur, dives into the fascinating world of protein engineering for cancer and autoimmune treatments. He shares his transformative journey from aspiring tennis player to leading immunology research. Topics include the ingenious application of AI in protein design, innovative strategies for enhancing clinical trials, and the significance of T-cell interactions in cancer therapies. Personal anecdotes of endurance running cleverly illustrate how these experiences spark creative breakthroughs in science.
Sep 26, 2024 • 1h 3min
Ep165: Zach Hornby on Tackling Cancer Drug Resistance
Zach Hornby, CEO of San Diego-based Boundless Bio, on tackling cancer drug resistance.
Sep 5, 2024 • 57min
Ep164: Ted Love and Alan Anderson on Raising the Bar for Sickle Cell Disease Patients
Ted Love, chairman of BIO, and Dr. Alan Anderson, executive director of Sickle Forward, on how to improve quality of life for sickle cell disease patients around the world.
Aug 14, 2024 • 1h 8min
Ep163: Sarah Boyce on RNA Medicines for Muscle Diseases
Sarah Boyce, CEO of Avidity Biosciences, shares her inspiring journey from Liverpool to leading a company focusing on RNA medicines for rare muscle diseases. She discusses the innovative therapies being developed for conditions like myotonic dystrophy and Duchenne muscular dystrophy. The conversation dives into the challenges of transitioning to a CEO role and the significance of emotional intelligence in leadership. Boyce also highlights advancements in RNA therapeutics, including promising drug trials and the importance of community engagement in biotechnology.
16 snips
Jul 16, 2024 • 1h 6min
Ep162: Sean McClain on AI for Biologic Drug Discovery
Sean McClain, CEO of Absci, discusses using AI to speed up biologic drug discovery. Topics include the upcoming clinical testing of an antibody drug for inflammatory bowel disease in 2025, integrating AI into drug discovery, the creative aspects of biologic drug discovery, engineering E. coli for biologic therapies, evolving business models in biologic drug discovery, unexpected discoveries in drug compound affinity, and revolutionizing drug discovery with AI-generated biologics.
Jul 1, 2024 • 1h 9min
Ep161: Jeff Stein on a Long-Lasting Flu Drug
Jeff Stein, CEO of San Diego-based Cidara Therapeutics, on a long-lasting drug against flu.
Jun 17, 2024 • 1h 9min
Ep160: Abe Ceesay on Precision Neuroscience
Abe Ceesay, CEO of Boston-based Rapport Therapeutics, on a precision medicine approach to neuroscience drug discovery.
Jun 3, 2024 • 1h 7min
Ep159: Jimi Olaghere on Being Functionally Cured of Sickle Cell Disease
Jimi Olaghere is one of the first patients to have been functionally cured of sickle cell disease with a CRISPR gene-edited cell therapy.
May 20, 2024 • 1h 1min
Ep158: David Younger and Randolph Lopez on SynBio & AI for Discovery
David Younger and Randolph Lopez, co-founders of A-Alpha Bio, discuss using synthetic biology and AI for drug discovery. They explore yeast as a platform, business representation challenges, and innovative approaches to developing antibodies. The podcast dives into how AI revolutionizes drug discovery and optimization, impacting human health through unique biological understanding.
May 1, 2024 • 57min
Ep157: Vineeta Agarwala of A16Z on Investing in AI for Drug Discovery
Vineeta Agarwala, a general partner at A16Z's Bio & Health fund, discusses AI's impact on drug discovery. Topics include AI automating tasks, learning from negative data, and the hype around AI in healthcare. She emphasizes the importance of small startups in curating data for AI, the necessity of patience in biotech investments, and the future of collaborative learning in drug discovery.
